KRW 4160.0
(-1.42%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 80.99 Billion KRW | 91.47% |
2022 | 42.3 Billion KRW | 67.55% |
2021 | 25.24 Billion KRW | 29.89% |
2020 | 19.43 Billion KRW | 10.01% |
2019 | 17.66 Billion KRW | 5.92% |
2018 | 16.68 Billion KRW | 0.0% |
2017 | - KRW | 0.0% |
2016 | - KRW | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | 22.71 Billion KRW | 31.92% |
2024 Q1 | 17.22 Billion KRW | -26.58% |
2023 FY | 80.99 Billion KRW | 91.47% |
2023 Q3 | 20.38 Billion KRW | -0.62% |
2023 Q4 | 23.45 Billion KRW | 15.07% |
2023 Q1 | 16.64 Billion KRW | -5.8% |
2023 Q2 | 20.51 Billion KRW | 23.2% |
2022 Q2 | 7.06 Billion KRW | 13.4% |
2022 FY | 42.3 Billion KRW | 67.55% |
2022 Q4 | 17.67 Billion KRW | 55.79% |
2022 Q3 | 11.34 Billion KRW | 60.66% |
2022 Q1 | 6.22 Billion KRW | -11.98% |
2021 FY | 25.24 Billion KRW | 29.89% |
2021 Q3 | 6.02 Billion KRW | 0.0% |
2021 Q4 | 7.07 Billion KRW | 17.49% |
2020 FY | 19.43 Billion KRW | 10.01% |
2019 FY | 17.66 Billion KRW | 5.92% |
2018 FY | 16.68 Billion KRW | 0.0% |
2017 FY | - KRW | 0.0% |
2016 FY | - KRW | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
HLB Pharmaceutical Co., Ltd | 135.95 Billion KRW | 40.422% |
CMG Pharmaceutical Co., Ltd. | 93.9 Billion KRW | 13.747% |
Celltrion Pharm, Inc. | 388.79 Billion KRW | 79.167% |
Huons Global Co., Ltd. | 758.37 Billion KRW | 89.32% |
DongKook Pharmaceutical Co., Ltd. | 730.99 Billion KRW | 88.92% |
Enzychem Lifesciences Corporation | 76.03 Billion KRW | -6.521% |
Humedix Co., Ltd. | 152.27 Billion KRW | 46.808% |
Boditech Med Inc. | 134.21 Billion KRW | 39.653% |
EuBiologics Co., Ltd. | 69.36 Billion KRW | -16.769% |
FutureChem Co.,Ltd | 13.96 Billion KRW | -479.878% |
Huons Co., Ltd. | 552 Billion KRW | 85.327% |
AptaBio Therapeutics Inc. | 323.86 Million KRW | -24909.351% |